Compare DexCom, Inc. (DXCM) vs Rivian Automotive, Inc. (RIVN) Price & Performance

DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.

The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.

Rivian (RIVN) trades at $16.005, down 2.35% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company continues to report significant losses, with a net income margin of -54.95% for 2025, though revenue has grown to $5.39 billion. Recent news highlights the R2 vehicle launch and a partnership with Uber, providing potential growth catalysts amid ongoing cash burn concerns.

The outlook remains speculative; RIVN offers high growth potential through new vehicle ramps and software margins, but substantial execution risks and negative cash flow pose threats to near-term stability. Analyst consensus is cautiously optimistic with a $18.70 price target, yet the stock's path depends heavily on achieving profitability milestones.